trending Market Intelligence /marketintelligence/en/news-insights/trending/teXOdJkU5l25JBZen3AO0w2 content esgSubNav
In This List

GB Sciences unit licenses IP to develop cannabis-based heart disease therapies

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


GB Sciences unit licenses IP to develop cannabis-based heart disease therapies

GB Sciences Inc. unit Growblox Life Sciences LLC has licensed intellectual property from Makai Biotechnology LLC.

The patent underlying the license was issued by the U.S. Patent and Trademark Office in July 2015 and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1.

TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.

Makai Biotechnology is a Hawaii-based cardiovascular therapy company developing novel therapies for the treatment of heart failure.